Enovis (ENOV) Total Non-Current Liabilities (2010 - 2026)
Enovis' (ENOV) quarterly Total Non-Current Liabilities came in at $1.9 billion in Q3 2026, down 3.6% year-over-year from $2.0 billion in Q3 2025, and down 2.07% quarter-over-quarter from $2.0 billion in Q2 2026.
Analysis
Enovis (ENOV) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Enovis (ENOV) has reported Total Non-Current Liabilities for 17 consecutive years, with $1.9 billion the latest figure, recorded in Q3 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 3.6% year-over-year to $1.9 billion in Q3 2026; TTM through Jul 2026 was $1.9 billion, a 3.6% decrease from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 1.45% from the prior year.
- Total Non-Current Liabilities was $1.9 billion for Q3 2026 at Enovis, down from $2.0 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $3.2 billion in Q2 2022 and troughed at $656.5 million in Q4 2022.
- A 5-year average of $1.6 billion and a median of $1.9 billion in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities tumbled 82.41% in 2022 and jumped 180.61% in 2024, its largest moves.
- Over 5 years, Total Non-Current Liabilities stood at $656.5 million in 2022, then jumped by 34.73% to $884.5 million in 2023, then jumped by 113.8% to $1.9 billion in 2024, then grew by 1.45% to $1.9 billion in 2025, then grew by 0.0% to $1.9 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $1.9 billion (Q3 2026), $2.0 billion (Q2 2026), and $1.9 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.70 Bn | 177.10 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 126.56 Bn | 121.34 Bn | 1.96 Bn | 1.92 Bn |
| 3 | Medtronic | 118.15 Bn | 109.33 Bn | 6.34 Bn | 40.46 Bn |
| 4 | Stryker | 104.94 Bn | 101.46 Bn | 4.50 Bn | 21.28 Bn |
| 5 | Boston Scientific | 64.79 Bn | 64.25 Bn | 3.85 Bn | 17.56 Bn |
| 6 | Edwards Lifesciences | 49.87 Bn | 45.62 Bn | 1.35 Bn | 2.57 Bn |
| 7 | Alcon | 33.04 Bn | 31.59 Bn | 1.68 Bn | 6.34 Bn |
| 8 | Dexcom | 32.07 Bn | 30.13 Bn | 830.00 Mn | 3.68 Bn |
| 9 | Steris | 20.78 Bn | 20.29 Bn | 684.20 Mn | 3.44 Bn |
| 10 | Enovis | 1.08 Bn | 1.07 Bn | 359.25 Mn | 1.92 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 1.92 Bn |
| Apr 3, 2026 | 1.96 Bn |
| Dec 31, 2025 | 1.92 Bn |
| Oct 3, 2025 | 1.97 Bn |
| Jul 4, 2025 | 1.99 Bn |
| Apr 4, 2025 | 1.89 Bn |
| Dec 31, 2024 | 1.89 Bn |
| Sep 27, 2024 | 1.90 Bn |
| Jun 28, 2024 | 1.90 Bn |
| Mar 29, 2024 | 1.92 Bn |
| Dec 31, 2023 | 884.46 Mn |
| Sep 29, 2023 | 799.46 Mn |
| Jun 30, 2023 | 801.24 Mn |
| Mar 31, 2023 | 683.79 Mn |
| Dec 31, 2022 | 656.46 Mn |
| Sep 30, 2022 | 905.95 Mn |
| Jul 1, 2022 | 868.01 Mn |
| Apr 1, 2022 | 3.24 Bn |
| Dec 31, 2021 | 3.73 Bn |
| Oct 1, 2021 | 2.71 Bn |